Calithera Biosciences Inc. (CALA)

5.80
NASDAQ : Health Technology
Prev Close 5.21
Day Low/High 5.28 / 6.70
52 Wk Low/High 3.55 / 6.90
Avg Volume 143.70K
Exchange NASDAQ
Shares Outstanding 39.24M
Market Cap 204.45M
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ADM, AFSI, CKX, EML, EVH, GDEN, MVC, MYGN, PANW, SO, SYKE, TARO Downgrades: IRCP, RMCF, UEIC, WYND Initiations: CALA, FG, MTNB Read on to get TheStreet Quant Ratings' detailed report:

Calithera Biosciences Reports Fourth Quarter 2017 Financial Results And Recent Highlights

Calithera Biosciences Reports Fourth Quarter 2017 Financial Results And Recent Highlights

-Calithera to Webcast Corporate Update on March 8, 2018

Commit To Purchase Calithera Biosciences At $5, Earn 27.5% Annualized Using Options

Commit To Purchase Calithera Biosciences At $5, Earn 27.5% Annualized Using Options

Investors considering a purchase of Calithera Biosciences, Inc. stock, but tentative about paying the going market price of $8.03/share, might benefit from considering selling puts among the alternative strategies at their disposal.

First Week of CALA April 20th Options Trading

First Week of CALA April 20th Options Trading

Investors in Calithera Biosciences, Inc. saw new options begin trading this week, for the April 20th expiration.

First Week of February 2018 Options Trading For Calithera Biosciences (CALA)

First Week of February 2018 Options Trading For Calithera Biosciences (CALA)

Investors in Calithera Biosciences, Inc. saw new options become available this week, for the February 2018 expiration.

Interesting CALA Put And Call Options For January 2018

Interesting CALA Put And Call Options For January 2018

Investors in Calithera Biosciences, Inc. saw new options become available this week, for the January 2018 expiration.

Oversold Conditions For Calithera Biosciences (CALA)

Oversold Conditions For Calithera Biosciences (CALA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Calithera Biosciences Stock Sees Short Interest Increase 10.6%

Calithera Biosciences Stock Sees Short Interest Increase 10.6%

The most recent short interest data has been released for the 10/31/2017 settlement date, which shows a 278,209 share increase in total short interest for Calithera Biosciences, Inc. , to 2,910,428, an increase of 10.57% since 10/13/2017.

Calithera Biosciences Reports Third Quarter 2017 Financial Results And Recent Highlights

Calithera Biosciences Reports Third Quarter 2017 Financial Results And Recent Highlights

Calithera to Webcast Clinical Update on CB-839 on November 11, 2017

Calithera Biosciences Reports Second Quarter 2017 Financial Results And Recent Highlights

Calithera Biosciences Reports Second Quarter 2017 Financial Results And Recent Highlights

-Calithera to Host Conference Call Today at 1:30 p.m. Pacific Time/ 4:30 p.m. Eastern Time

CALA Crosses Above Average Analyst Target

CALA Crosses Above Average Analyst Target

In recent trading, shares of Calithera Biosciences, Inc. have crossed above the average analyst 12-month target price of $19.00, changing hands for $20.00/share.

Market Needs to Keep Going in One Direction

Market Needs to Keep Going in One Direction

There is nothing to indicate that this period of chaotic rotation has ended.

TheStreet Quant Rating: D (Sell)